A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy

EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines

(2014) T. A. Haigh et al.   JOURNAL OF IMMUNOLOGY

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

(2009) H. E. Heslop et al.   BLOOD

Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection

(2009) S. Iwata et al.   JOURNAL OF GENERAL VIROLOGY

Cyclical Expression of EBV Latent Membrane Protein 1 in EBV-Transformed B Cells Underpins Heterogeneity of Epitope Presentation and CD8+ T Cell Recognition

(2009) J. M. Brooks et al.   JOURNAL OF IMMUNOLOGY

Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies

(2009) J Iqbal et al.   LEUKEMIA

The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation

(2009) Jianmin Zuo et al.   PLoS Pathogens

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

(2008) W.-y. Au et al.   BLOOD

Induction of EBV-Latent Membrane Protein 1-Specific MHC Class II-Restricted T-Cell Responses against Natural Killer Lymphoma Cells

(2008) H. Kobayashi et al.   CANCER RESEARCH

Epstein-Barr virus nuclear antigen 1-specific CD4+T cells directly kill Epstein-Barr virus-carrying natural killer and T cells

(2008) Ayako Demachi-Okamura et al.   CANCER SCIENCE